We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Taysha Gene Therapies Inc | NASDAQ:TSHA | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.13 | -5.14% | 2.40 | 0.50 | 3.00 | 2.57 | 2.30 | 2.54 | 1,407,720 | 05:00:04 |
From May 2023 to May 2024
By Ben Glickman
Taysha Gene Therapies will discontinue development of its TSHA-120 program to treat giant axonal neuropathy after receiving feedback from the U.S. Food and Drug Administration.
The Dallas-based gene-therapy developer said that it had received Type C meeting feedback from the FDA. Chief Executive Sean Nolan said that the feedback pointed out "challenges related to the feasibility of the study designs" to support approval by the FDA.
The company will pursue external strategic options for TSHA-120, which is meant to extend Taysha's cash runway into the fourth quarter of 2025.
Taysha said that Astellas Gene Therapy had decided not to exercise its exclusive license option under a prior agreement between the two companies.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
September 19, 2023 16:37 ET (20:37 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Taysha Gene Therapies Chart |
1 Month Taysha Gene Therapies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
